{"transactions":[{"id":722833,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T23:00:10.000Z","date":"2026-06-26","kind":"grant","planned":false,"acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option vest in full upon the earlier of (i) June 26, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":15000,"derivative":{"exercise_price":37.34,"expiration_date":"2036-06-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001193125-26-291054","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000119312526291054/ownership.xml","form_type":"4"}},{"id":805709,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."}],"balance_after":325000,"derivative":{"exercise_price":1.33,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805708,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."}],"balance_after":0,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805707,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":256300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."}],"balance_after":256300,"derivative":{"exercise_price":1.33,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":256300},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805706,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":256300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."}],"balance_after":0,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":256300},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805705,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":206300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033."}],"balance_after":206300,"derivative":{"exercise_price":1.33,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":206300},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805704,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":206300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The expiration date has been updated from the Form 4 originally filed on January 27, 2023 from January 24, 2033 to the correct expiration date of January 25, 2033."}],"balance_after":0,"derivative":{"exercise_price":34.65,"expiration_date":"2033-01-25","underlying":"Common Stock","underlying_shares":206300},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805703,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032."}],"balance_after":440000,"derivative":{"exercise_price":1.33,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805702,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":440000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The expiration date has been updated from the Form 4 originally filed on February 2, 2022 from January 25, 2032 to the correct expiration date of January 26, 2032."}],"balance_after":0,"derivative":{"exercise_price":11.86,"expiration_date":"2032-01-26","underlying":"Common Stock","underlying_shares":440000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805701,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031."}],"balance_after":250000,"derivative":{"exercise_price":1.33,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805700,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The expiration date has been updated from the Form 4 originally filed on January 26, 2021 from January 22, 2031 to the correct expiration date of January 23, 2031."}],"balance_after":0,"derivative":{"exercise_price":26.5,"expiration_date":"2031-01-23","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805699,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":327262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030."}],"balance_after":327262,"derivative":{"exercise_price":1.33,"expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":327262},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805698,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":327262,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from March 30, 2030 to the correct expiration date of March 31, 2030."}],"balance_after":0,"derivative":{"exercise_price":6.22,"expiration_date":"2030-03-31","underlying":"Common Stock","underlying_shares":327262},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805697,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"grant","planned":false,"acquired":true,"shares":146841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The closing price per share of the Issuer's common stock on the Effective Date. Under the terms of the Repricing, a repriced stock option award will revert to its original exercise price if exercised during the Retention Period. The \"Retention Period\" commenced on the Effective Date and ends on the earliest of the following: (i) the eighteen-month anniversary of the Effective Date; (ii) the consummation of a Corporate Transaction (as defined by the 2015 Plan) or a Sale Event (as defined by the 2020 Plan); and (iii) the Reporting Person's (a) termination without cause (as defined in the Reporting Person's severance plan) or due to a reduction in force, (b) death or termination due to disability, or (c) resignation from service for good reason (as defined in the Reporting Person's severance plan)."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The repriced options will also revert to its original exercise price if the Reporting Person (i) is terminated for cause (as defined in the Reporting Person's severance plan) or (ii) resigns prior to the end of the Retention Period, except for good reason (as defined in the Reporting Person's severance plan)."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029."}],"balance_after":146841,"derivative":{"exercise_price":1.33,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":146841},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":805696,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-17T20:42:38.000Z","date":"2026-04-17","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":146841,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On April 15, 2026, the Issuer's board of directors approved an option repricing (the \"Repricing\"), effective April 17, 2026 (the \"Effective Date\"), for all stock options granted on or before March 1, 2025 to the Issuer's current employees, including the Reporting Person. All of the other terms of the options remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Issuer's 2015 Equity Incentive Plan, as amended (the \"2015 Plan\"), or the Issuer's 2020 Stock Option and Incentive Plan, as amended (the \"2020 Plan\"), as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on the Reporting Person's applicable Form 3 or Form 4, subject to the Reporting Person's continued service to the Issuer as of the applicable vesting dates."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The expiration date has been updated from the Form 3 originally filed on June 2, 2020 from January 23, 2029 to the correct expiration date of January 24, 2029."}],"balance_after":0,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-24","underlying":"Common Stock","underlying_shares":146841},"source":{"system":"sec-edgar","filing":"0001746473-26-000053","document":"wk-form4_1776458555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000053/wk-form4_1776458555.xml","form_type":"4"}},{"id":931207,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-26T21:36:35.000Z","date":"2026-01-22","kind":"grant","planned":false,"acquired":true,"shares":1230000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":1230000,"derivative":{"exercise_price":1.3,"expiration_date":"2036-01-22","underlying":"Common Stock","underlying_shares":1230000},"source":{"system":"sec-edgar","filing":"0001746473-26-000017","document":"wk-form4_1769463393.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000017/wk-form4_1769463393.xml","form_type":"4"}},{"id":933451,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-23T02:38:33.000Z","date":"2026-01-20","kind":"sale","planned":true,"acquired":false,"shares":89375,"price":1.28,"value":114400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's share represents the weighted average of all shares sold by a broker at prices ranging from $1.245 to $1.33, inclusive, on January 20, 2026 through January 22, 2026 on behalf of a group on employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,959 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase program."}],"balance_after":505601,"source":{"system":"sec-edgar","filing":"0001746473-26-000009","document":"wk-form4_1769135911.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647326000009/wk-form4_1769135911.xml","form_type":"4"}},{"id":1105079,"issuer":{"id":2452,"kind":"organization","name":"Septerna, Inc.","symbol":"SEPN"},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T22:41:34.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":16623,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option will vest in full upon the earlier of (i) June 17, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":16623,"derivative":{"exercise_price":10.24,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":16623},"source":{"system":"sec-edgar","filing":"0000950170-25-088620","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000095017025088620/ownership.xml","form_type":"4"}},{"id":1294559,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-27T22:58:27.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":325000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":325000,"derivative":{"exercise_price":11.14,"expiration_date":"2035-01-23","underlying":"Common Stock","underlying_shares":325000},"source":{"system":"sec-edgar","filing":"0001746473-25-000009","document":"wk-form4_1738018700.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647325000009/wk-form4_1738018700.xml","form_type":"4"}},{"id":1294558,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-27T22:58:27.000Z","date":"2025-01-23","kind":"grant","planned":false,"acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":593017,"source":{"system":"sec-edgar","filing":"0001746473-25-000009","document":"wk-form4_1738018700.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647325000009/wk-form4_1738018700.xml","form_type":"4"}},{"id":1297776,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-22T23:07:10.000Z","date":"2025-01-17","kind":"sale","planned":true,"acquired":false,"shares":52419,"price":11.2011,"value":587150.4609,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $11.03 to $11.695, inclusive, on January 17, 2025 and January 21, 2025 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":430517,"source":{"system":"sec-edgar","filing":"0001746473-25-000006","document":"wk-form4_1737587223.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647325000006/wk-form4_1737587223.xml","form_type":"4"}},{"id":1455363,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-07-12T22:22:25.000Z","date":"2024-07-10","kind":"sale","planned":true,"acquired":false,"shares":38710,"price":11.56,"value":447487.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $10.785 to $12.58, inclusive, between July 10, 2024 and July 11, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":482936,"source":{"system":"sec-edgar","filing":"0001746473-24-000123","document":"wk-form4_1720822935.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647324000123/wk-form4_1720822935.xml","form_type":"4"}},{"id":1456308,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-07-11T20:47:45.000Z","date":"2024-07-09","kind":"grant","planned":false,"acquired":true,"shares":75625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 75,625 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,489 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":521646,"source":{"system":"sec-edgar","filing":"0001746473-24-000113","document":"wk-form4_1720730857.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647324000113/wk-form4_1720730857.xml","form_type":"4"}},{"id":1672151,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-24T21:56:54.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":256300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":256300,"derivative":{"exercise_price":17.44,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":256300},"source":{"system":"sec-edgar","filing":"0001746473-24-000012","document":"wk-form4_1706133403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647324000012/wk-form4_1706133403.xml","form_type":"4"}},{"id":1672150,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-24T21:56:54.000Z","date":"2024-01-23","kind":"grant","planned":false,"acquired":true,"shares":128150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2024, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":444532,"source":{"system":"sec-edgar","filing":"0001746473-24-000012","document":"wk-form4_1706133403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647324000012/wk-form4_1706133403.xml","form_type":"4"}},{"id":1675348,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-19T22:19:08.000Z","date":"2024-01-17","kind":"sale","planned":true,"acquired":false,"shares":25721,"price":17.23,"value":443172.83,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $16.33 to $17.90, inclusive, between January 17, 2024 and January 18, 2024 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted restricted stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":316382,"source":{"system":"sec-edgar","filing":"0001746473-24-000003","document":"wk-form4_1705702740.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000174647324000003/wk-form4_1705702740.xml","form_type":"4"}},{"id":1826944,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-07-20T00:20:31.000Z","date":"2023-07-17","kind":"sale","planned":true,"acquired":false,"shares":70150,"price":18.0091,"value":1263338.365,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan on behalf of the Reporting Person in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $17.63 to $18.47, inclusive, between July 17, 2023 and July 19, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":342103,"source":{"system":"sec-edgar","filing":"0001209191-23-042823","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000120919123042823/doc4.xml","form_type":"4"}},{"id":1827899,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-07-18T23:14:23.000Z","date":"2023-07-14","kind":"grant","planned":false,"acquired":true,"shares":137500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On July 14, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 137,500 shares."}],"balance_after":412253,"source":{"system":"sec-edgar","filing":"0001209191-23-042654","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000120919123042654/doc4.xml","form_type":"4"}},{"id":1854535,"issuer":{"id":112267,"kind":"organization","name":"SQZ Biotechnologies Co","symbol":"SQZ"},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2023-06-15T20:40:52.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":39875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and become exercisable on the earlier of (i) June 14, 2024 or (ii) the day immediately prior to the date of the next annual meeting of stockholders following the date of grant, in each case subject to the recipient's continued service on the Board at such time."}],"balance_after":39875,"derivative":{"exercise_price":0.539,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":39875},"source":{"system":"sec-edgar","filing":"0001209191-23-037372","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000120919123037372/doc4.xml","form_type":"4"}},{"id":1932572,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-04-03T22:46:00.000Z","date":"2023-03-30","kind":"sale","planned":true,"acquired":false,"shares":35339,"price":26.5209,"value":937222.0851,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4."}],"balance_after":274753,"source":{"system":"sec-edgar","filing":"0001209191-23-022362","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000120919123022362/doc4.xml","form_type":"4"}},{"id":1934067,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-31T21:54:20.000Z","date":"2023-03-29","kind":"grant","planned":false,"acquired":true,"shares":68749,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On March 29, 2023, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 68,749 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,231 shares of Common Stock acquired by the Reporting Person pursuant to an Employee Stock Purchase Plan program."}],"balance_after":310092,"source":{"system":"sec-edgar","filing":"0001209191-23-021915","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000120919123021915/doc4.xml","form_type":"4"}},{"id":2030728,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:45:21.000Z","date":"2023-02-03","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":327262,"derivative":{"exercise_price":6.22,"expiration_date":"2030-03-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-004735","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123004735/form4.xml","form_type":"4"}},{"id":2030727,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-06T22:45:21.000Z","date":"2023-02-02","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":342262,"derivative":{"exercise_price":6.22,"expiration_date":"2030-03-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-004735","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123004735/form4.xml","form_type":"4"}},{"id":2030726,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-06T22:45:21.000Z","date":"2023-02-03","kind":"sale","acquired":false,"shares":5262,"price":34.0768,"value":179312.1216,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.56, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4."}],"balance_after":240112,"source":{"system":"sec-edgar","filing":"0001140361-23-004735","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123004735/form4.xml","form_type":"4"}},{"id":2030725,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-06T22:45:21.000Z","date":"2023-02-03","kind":"sale","acquired":false,"shares":9738,"price":33.3629,"value":324887.9202,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.84 to $33.83, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."}],"balance_after":245374,"source":{"system":"sec-edgar","filing":"0001140361-23-004735","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123004735/form4.xml","form_type":"4"}},{"id":2030724,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-06T22:45:21.000Z","date":"2023-02-03","kind":"exercise","acquired":true,"shares":15000,"price":6.22,"value":93300.0,"ownership":{"direct":true},"balance_after":255112,"source":{"system":"sec-edgar","filing":"0001140361-23-004735","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123004735/form4.xml","form_type":"4"}},{"id":2030723,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-06T22:45:21.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":1605,"price":34.9566,"value":56105.343,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.69 to $35.48, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":240112,"source":{"system":"sec-edgar","filing":"0001140361-23-004735","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123004735/form4.xml","form_type":"4"}},{"id":2030722,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-06T22:45:21.000Z","date":"2023-02-02","kind":"sale","acquired":false,"shares":13395,"price":34.1265,"value":457124.4675,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.65 to $34.60, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":241717,"source":{"system":"sec-edgar","filing":"0001140361-23-004735","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123004735/form4.xml","form_type":"4"}},{"id":2030721,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-06T22:45:21.000Z","date":"2023-02-02","kind":"exercise","acquired":true,"shares":15000,"price":6.22,"value":93300.0,"ownership":{"direct":true},"balance_after":255112,"source":{"system":"sec-edgar","filing":"0001140361-23-004735","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123004735/form4.xml","form_type":"4"}},{"id":2038628,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T02:43:55.000Z","date":"2023-02-01","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":357262,"derivative":{"exercise_price":6.22,"expiration_date":"2030-03-30","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038627,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-31","kind":"exercise","acquired":false,"shares":4461,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":372262,"derivative":{"exercise_price":6.22,"expiration_date":"2030-03-30","underlying":"Common Stock","underlying_shares":4461},"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038626,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-31","kind":"exercise","acquired":false,"shares":10539,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":146841,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":10539},"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038625,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-30","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":157380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038624,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":105,"price":35.5548,"value":3733.254,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.55 to $35.65, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4."}],"balance_after":240112,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038623,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":5440,"price":34.778,"value":189192.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.52 to $35.42, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (5) to this Form 4."}],"balance_after":240217,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038622,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-02-01","kind":"sale","acquired":false,"shares":9455,"price":34.145,"value":322840.975,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.52 to $34.50, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."}],"balance_after":245657,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038621,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-02-01","kind":"exercise","acquired":true,"shares":15000,"price":6.22,"value":93300.0,"ownership":{"direct":true},"balance_after":255112,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038620,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-31","kind":"sale","acquired":false,"shares":15000,"price":34.917,"value":523755.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."}],"balance_after":240112,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038619,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-31","kind":"exercise","acquired":true,"shares":4461,"price":6.22,"value":27747.42,"ownership":{"direct":true},"balance_after":255112,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038618,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-31","kind":"exercise","acquired":true,"shares":10539,"price":2.08,"value":21921.12,"ownership":{"direct":true},"balance_after":250651,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038617,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-30","kind":"sale","acquired":false,"shares":3605,"price":34.657,"value":124938.485,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.56 to $34.92, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":240112,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038616,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-30","kind":"sale","acquired":false,"shares":11395,"price":33.9778,"value":387177.031,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.56 to $34.55, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":243717,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2038615,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-02T02:43:55.000Z","date":"2023-01-30","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":255112,"source":{"system":"sec-edgar","filing":"0001140361-23-003977","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003977/form4.xml","form_type":"4"}},{"id":2043812,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-26","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":172380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043811,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-26","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":187380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043810,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":206300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":206300,"derivative":{"exercise_price":34.65,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":206300},"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043809,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":221,"price":36.64,"value":8097.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":409317,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043808,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":9779,"price":35.0913,"value":343157.8227,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.63 to $36.54, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":409538,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043807,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":6302,"price":36.0589,"value":227243.1878,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.87 to $36.45, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4."}],"balance_after":240112,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043806,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-27","kind":"sale","acquired":false,"shares":8698,"price":35.4157,"value":308045.7586,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.87 to $35.85, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4."}],"balance_after":246414,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043805,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-27","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":255112,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043804,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-26","kind":"sale","acquired":false,"shares":15000,"price":35.095,"value":526425.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.00 to $35.43, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":419317,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043803,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-26","kind":"sale","acquired":false,"shares":15000,"price":35.2911,"value":529366.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."}],"balance_after":240112,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043802,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-26","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":255112,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2043801,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-28T00:15:21.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":146300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2023, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":240112,"source":{"system":"sec-edgar","filing":"0001140361-23-003177","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123003177/form4.xml","form_type":"4"}},{"id":2046487,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-25","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":202380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046486,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-24","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":217380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046485,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-23","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":232380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046484,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":1696,"price":33.2897,"value":56459.3312,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.00 to  $33.66, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (8) to this Form 4."}],"balance_after":93812,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046483,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":13304,"price":32.4006,"value":431057.5824,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.95 to $32.90, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (7) to this Form 4."}],"balance_after":95508,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046482,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-25","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":108812,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046481,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-24","kind":"sale","acquired":false,"shares":15000,"price":30.8926,"value":463389.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $30.42 to $31.38, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (6) to this Form 4."}],"balance_after":93812,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046480,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-24","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":108812,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046479,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":15000,"price":35,"value":525000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Shares held by The Coulie/Leyman Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose."}],"balance_after":434317,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046478,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":4850,"price":34.9288,"value":169404.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.43 to $35.00, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (3) to this Form 4."}],"balance_after":93812,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046477,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-23","kind":"sale","acquired":false,"shares":10150,"price":33.7106,"value":342162.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.40 to $34.34, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":98662,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2046476,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-26T02:00:55.000Z","date":"2023-01-23","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":108812,"source":{"system":"sec-edgar","filing":"0001140361-23-002786","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123002786/form4.xml","form_type":"4"}},{"id":2058990,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-10T01:16:06.000Z","date":"2023-01-09","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":247380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001140361-23-001119","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123001119/form4.xml","form_type":"4"}},{"id":2058989,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-10T01:16:06.000Z","date":"2023-01-06","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":252380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-001119","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123001119/form4.xml","form_type":"4"}},{"id":2058988,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-10T01:16:06.000Z","date":"2023-01-09","kind":"sale","acquired":false,"shares":5000,"price":19.1658,"value":95829.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.50, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":93812,"source":{"system":"sec-edgar","filing":"0001140361-23-001119","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123001119/form4.xml","form_type":"4"}},{"id":2058987,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-10T01:16:06.000Z","date":"2023-01-09","kind":"exercise","acquired":true,"shares":5000,"price":2.08,"value":10400.0,"ownership":{"direct":true},"balance_after":98812,"source":{"system":"sec-edgar","filing":"0001140361-23-001119","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123001119/form4.xml","form_type":"4"}},{"id":2058986,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-10T01:16:06.000Z","date":"2023-01-06","kind":"sale","acquired":false,"shares":15000,"price":19.0389,"value":285583.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.17, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":93812,"source":{"system":"sec-edgar","filing":"0001140361-23-001119","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123001119/form4.xml","form_type":"4"}},{"id":2058985,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-10T01:16:06.000Z","date":"2023-01-06","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":108812,"source":{"system":"sec-edgar","filing":"0001140361-23-001119","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123001119/form4.xml","form_type":"4"}},{"id":2062999,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-06T00:44:30.000Z","date":"2023-01-04","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":267380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-000721","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123000721/form4.xml","form_type":"4"}},{"id":2062998,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2023-01-06T00:44:30.000Z","date":"2023-01-03","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":282380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001140361-23-000721","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123000721/form4.xml","form_type":"4"}},{"id":2062997,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-06T00:44:30.000Z","date":"2023-01-04","kind":"sale","acquired":false,"shares":15000,"price":19.0627,"value":285940.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.185, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":93812,"source":{"system":"sec-edgar","filing":"0001140361-23-000721","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123000721/form4.xml","form_type":"4"}},{"id":2062996,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-06T00:44:30.000Z","date":"2023-01-04","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":108812,"source":{"system":"sec-edgar","filing":"0001140361-23-000721","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123000721/form4.xml","form_type":"4"}},{"id":2062995,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-06T00:44:30.000Z","date":"2023-01-03","kind":"sale","acquired":false,"shares":15000,"price":19.3301,"value":289951.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.80, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":93812,"source":{"system":"sec-edgar","filing":"0001140361-23-000721","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123000721/form4.xml","form_type":"4"}},{"id":2062994,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-01-06T00:44:30.000Z","date":"2023-01-03","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"balance_after":108812,"source":{"system":"sec-edgar","filing":"0001140361-23-000721","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036123000721/form4.xml","form_type":"4"}},{"id":2078866,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-22T02:32:37.000Z","date":"2022-12-20","kind":"sale","acquired":false,"shares":34212,"price":19.1024,"value":653531.3088,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker at prices ranging from $18.4049 to $19.64, inclusive, on December 20, 2022 and December 21, 2022 on behalf of a group of employees of the Issuer to satisfy the payment of withholding tax liability of such employee in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (2) to this Form 4."}],"balance_after":93812,"source":{"system":"sec-edgar","filing":"0001140361-22-046570","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036122046570/form4.xml","form_type":"4"}},{"id":2078865,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-12-22T02:32:37.000Z","date":"2022-12-19","kind":"grant","acquired":true,"shares":68751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 28, 2022, the Reporting Person was granted 275,000 performance-vested stock units, the vesting of which are subject to the achievement of various pre-established performance criteria. On December 19, 2022, the Compensation Committee of the Issuer's Board of Directors certified the achievement of an operational performance criteria, resulting in the vesting of 68,751 shares."}],"balance_after":128024,"source":{"system":"sec-edgar","filing":"0001140361-22-046570","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000114036122046570/form4.xml","form_type":"4"}},{"id":2159425,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-09-14T21:31:35.000Z","date":"2022-09-12","kind":"exercise","acquired":false,"shares":12502,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":297380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":12502},"source":{"system":"sec-edgar","filing":"0001567619-22-017430","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922017430/doc1.xml","form_type":"4"}},{"id":2159424,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-14T21:31:35.000Z","date":"2022-09-12","kind":"sale","acquired":false,"shares":12502,"price":22.5445,"value":281851.339,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.50 to $22.69, inclusive. The Reporting Person undertakes to provide to Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4."}],"balance_after":59273,"source":{"system":"sec-edgar","filing":"0001567619-22-017430","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922017430/doc1.xml","form_type":"4"}},{"id":2159423,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-09-14T21:31:35.000Z","date":"2022-09-12","kind":"exercise","acquired":true,"shares":12502,"price":2.08,"value":26004.16,"ownership":{"direct":true},"balance_after":71775,"source":{"system":"sec-edgar","filing":"0001567619-22-017430","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922017430/doc1.xml","form_type":"4"}},{"id":2208070,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-13T23:05:39.000Z","date":"2022-07-12","kind":"exercise","acquired":false,"shares":12498,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":309882,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":12498},"source":{"system":"sec-edgar","filing":"0001567619-22-013993","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922013993/doc1.xml","form_type":"4"}},{"id":2208069,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (right to buy)","published_at":"2022-07-13T23:05:39.000Z","date":"2022-07-11","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"1/48th of the shares subject to the original option grant vest and become exercisable in substantially equal installments on each monthly anniversary of January 24, 2019, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":322380,"derivative":{"exercise_price":2.08,"expiration_date":"2029-01-23","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001567619-22-013993","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922013993/doc1.xml","form_type":"4"}},{"id":2208068,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-13T23:05:39.000Z","date":"2022-07-12","kind":"sale","acquired":false,"shares":12498,"price":22.5,"value":281205.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020."}],"balance_after":59273,"source":{"system":"sec-edgar","filing":"0001567619-22-013993","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922013993/doc1.xml","form_type":"4"}},{"id":2208067,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-13T23:05:39.000Z","date":"2022-07-12","kind":"exercise","acquired":true,"shares":12498,"price":2.08,"value":25995.84,"ownership":{"direct":true},"balance_after":71771,"source":{"system":"sec-edgar","filing":"0001567619-22-013993","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922013993/doc1.xml","form_type":"4"}},{"id":2208066,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-13T23:05:39.000Z","date":"2022-07-11","kind":"sale","acquired":false,"shares":15000,"price":22.5,"value":337500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020."}],"balance_after":59273,"source":{"system":"sec-edgar","filing":"0001567619-22-013993","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922013993/doc1.xml","form_type":"4"}},{"id":2208065,"issuer":{"id":7022,"kind":"organization","name":"PLIANT THERAPEUTICS, INC."},"owners":[{"id":34489,"kind":"person","name":"Coulie Bernard","position":1,"cik":"0001808895","reported_name":"Coulie Bernard","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-07-13T23:05:39.000Z","date":"2022-07-11","kind":"exercise","acquired":true,"shares":15000,"price":2.08,"value":31200.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,433 shares of Common Stock acquired by the reporting person pursuant to an employee stock purchase program."}],"balance_after":74273,"source":{"system":"sec-edgar","filing":"0001567619-22-013993","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808895/000156761922013993/doc1.xml","form_type":"4"}}],"next_cursor":"2022-07-13T23:05:39.000000Z,2208065"}